UY28635A1 - Derivados de pirazolilo, procedimiento de preparación y productos intermedios de este procedimiento a modo de medicamentos y composiciones farmacéuticas que los contienen. - Google Patents

Derivados de pirazolilo, procedimiento de preparación y productos intermedios de este procedimiento a modo de medicamentos y composiciones farmacéuticas que los contienen.

Info

Publication number
UY28635A1
UY28635A1 UY28635A UY28635A UY28635A1 UY 28635 A1 UY28635 A1 UY 28635A1 UY 28635 A UY28635 A UY 28635A UY 28635 A UY28635 A UY 28635A UY 28635 A1 UY28635 A1 UY 28635A1
Authority
UY
Uruguay
Prior art keywords
radical
procedure
nhc
halogen
nitrogen
Prior art date
Application number
UY28635A
Other languages
English (en)
Inventor
Genevois-Borella Arielle
Malleron Jean-Luc
Bouquerel Jean
Doerflinger Gilles
Bohme Andrees
Touyer Gaetan
Terrier Corinne
Mignani Serge
Evers Michel
El-Ahmad Youssef
Sabuco Jean-Francois
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY28635A1 publication Critical patent/UY28635A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos derivados de fórmula general (I) en la que :A es, si está presente, un radical alquilo (C1-C6), un radical alquenilo (C3-C6), un radical alquinilo (C3-C6), un radical cicloalquilo (C3-C7), un radical cicloalquenilo (C5-C7), R1 es una agrupación NR6R7, azacicloalquilo (C4-C7), azacicloalquenilo (C5-C7), azabicicloalquilo (C5-C9), azabicicloalquenilo (C5-C9); A-R1 es tal que el nitrógeno de R1 y el nitrógeno 1 del pirazol están separados obligatoriamente por al menos dos átomos de carbono, R3 es un radical H, halógeno, OH, SH, NH2, ORc, SRc, SORa, SO2Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra, NHSO2Ra, R4 es un radical arilo o heteroarilo; R5 es un radical H, halógeno, CF3, CHF2, CH2F, alquilo (C1-C6) lineal o ramificado, cicloalquilo (C3-C7), sus racémicos, enantiómeros, diastereoisómeros y mezclas de los mismos, sus tautómeros y sus sales farmacéuticamente aceptables.La presente invención se refiere a nuevos derivados de fórmula general (I) en la que :A es, si está presente, un radical alquilo (C1-C6), un radical alquenilo (C3-C6), un radical alquinilo (C3-C6), un radical cicloalquilo (C3-C7), un radical cicloalquenilo (C5-C7), R1 es una agrupación NR6R7, azacicloalquilo (C4-C7), azacicloalquenilo (C5-C7), azabicicloalquilo (C5-C9), azabicicloalquenilo (C5-C9); A-R1 es tal que el nitrógeno de R1 y el nitrógeno 1 del pirazol están separados obligatoriamente por al menos dos átomos de carbono, R3 es un radical H, halógeno, OH, SH, NH2, ORc, SRc, SORa, SO2Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra, NHSO2Ra, R4 es un radical arilo o heteroarilo; R5 es un radical H, halógeno, CF3, CHF2, CH2F, alquilo (C1-C6) lineal o ramificado, cicloalquilo (C3-C7), sus racémicos, enantiómeros, diastereoicómeros y mezclas de los mismos, sus tautómeros y sus sales farmacéuticamente aceptables.
UY28635A 2003-11-25 2004-11-25 Derivados de pirazolilo, procedimiento de preparación y productos intermedios de este procedimiento a modo de medicamentos y composiciones farmacéuticas que los contienen. UY28635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313775A FR2862647B1 (fr) 2003-11-25 2003-11-25 Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
UY28635A1 true UY28635A1 (es) 2005-06-30

Family

ID=34531236

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28635A UY28635A1 (es) 2003-11-25 2004-11-25 Derivados de pirazolilo, procedimiento de preparación y productos intermedios de este procedimiento a modo de medicamentos y composiciones farmacéuticas que los contienen.

Country Status (31)

Country Link
US (2) US7524838B2 (es)
EP (1) EP1689720B1 (es)
JP (1) JP4833078B2 (es)
KR (1) KR20060123193A (es)
CN (2) CN102174017A (es)
AR (1) AR046632A1 (es)
AT (1) ATE428699T1 (es)
AU (1) AU2004293214B2 (es)
BR (1) BRPI0416926A (es)
CA (1) CA2544519A1 (es)
CY (1) CY1110333T1 (es)
DE (1) DE602004020660D1 (es)
DK (1) DK1689720T3 (es)
ES (1) ES2325446T3 (es)
FR (1) FR2862647B1 (es)
HR (1) HRP20090391T1 (es)
IL (1) IL175539A0 (es)
MA (1) MA28147A1 (es)
MY (1) MY141218A (es)
NO (1) NO20062954L (es)
NZ (1) NZ548071A (es)
PL (1) PL1689720T3 (es)
PT (1) PT1689720E (es)
RS (1) RS50836B (es)
RU (2) RU2376290C2 (es)
SG (1) SG131945A1 (es)
SI (1) SI1689720T1 (es)
TW (1) TWI343811B (es)
UY (1) UY28635A1 (es)
WO (1) WO2005051917A1 (es)
ZA (2) ZA200604051B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2129225B1 (en) * 2007-04-03 2012-12-05 E. I. Du Pont de Nemours and Company Substituted benzene fungicides
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2009050186A1 (en) 2007-10-18 2009-04-23 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
ES2442932T3 (es) 2008-03-19 2014-02-14 Janssen Pharmaceutica N.V. 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
EA018187B1 (ru) 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
EP2151434A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
US8791144B2 (en) 2009-09-17 2014-07-29 Janssen Pharmaceutica Nv Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
CA2775840C (en) 2009-10-01 2018-02-06 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2015067782A1 (en) * 2013-11-08 2015-05-14 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3105225A1 (en) 2014-02-12 2016-12-21 iTeos Therapeutics Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
CA2948842C (en) 2014-05-15 2019-09-24 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
RU2667062C1 (ru) * 2015-02-27 2018-09-14 Торэй Индастриз, Инк. Производное циклического амина и его фармацевтическое применение
SG11201706992TA (en) 2015-03-17 2017-09-28 Pfizer Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2017025868A1 (en) 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
KR102625861B1 (ko) * 2016-06-28 2024-01-17 삼성디스플레이 주식회사 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN109563072B (zh) * 2016-08-26 2021-05-11 东丽株式会社 环状胺衍生物的结晶及其医药用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4069685A1 (en) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2014831A1 (en) 1968-08-01 1970-04-24 Sogeras Quinuclidinyl and quinuclidinylalkyl ethers with cholino - lytic, antihistaminic and neurosedative activity
ATE136031T1 (de) * 1989-10-07 1996-04-15 Beecham Group Plc Azabizyklische verbindungen, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DK0588917T3 (da) * 1991-05-29 2001-02-12 Abbott Lab Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
GB9500580D0 (en) * 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
EP1002871A1 (en) 1998-11-17 2000-05-24 Eidgenössische Technische Hochschule (ETH) Zürich Process for preparing optically active 3-hydroxy-pyrrolidine derivatives by enzymatic hydroxylation
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS

Also Published As

Publication number Publication date
AR046632A1 (es) 2005-12-14
CN1906172A (zh) 2007-01-31
RS50836B (sr) 2010-08-31
NZ548071A (en) 2010-03-26
RU2009122368A (ru) 2010-12-20
TWI343811B (en) 2011-06-21
WO2005051917A9 (fr) 2005-09-29
KR20060123193A (ko) 2006-12-01
US20090170833A1 (en) 2009-07-02
EP1689720B1 (fr) 2009-04-15
AU2004293214B2 (en) 2011-04-21
EP1689720A1 (fr) 2006-08-16
RU2006122553A (ru) 2008-01-10
WO2005051917A1 (fr) 2005-06-09
HRP20090391T1 (en) 2009-08-31
AU2004293214A1 (en) 2005-06-09
JP2007536213A (ja) 2007-12-13
US7524838B2 (en) 2009-04-28
BRPI0416926A (pt) 2007-01-16
WO2005051917B1 (fr) 2005-08-04
FR2862647B1 (fr) 2008-07-04
TW200529826A (en) 2005-09-16
JP4833078B2 (ja) 2011-12-07
ZA200604051B (en) 2007-12-27
ES2325446T3 (es) 2009-09-04
US8048893B2 (en) 2011-11-01
MA28147A1 (fr) 2006-09-01
MY141218A (en) 2010-03-31
US20050165005A1 (en) 2005-07-28
PT1689720E (pt) 2009-07-20
ATE428699T1 (de) 2009-05-15
DE602004020660D1 (de) 2009-05-28
CA2544519A1 (fr) 2005-06-09
CN102174017A (zh) 2011-09-07
CY1110333T1 (el) 2015-01-14
RU2376290C2 (ru) 2009-12-20
NO20062954L (no) 2006-08-25
DK1689720T3 (da) 2009-08-10
FR2862647A1 (fr) 2005-05-27
SI1689720T1 (sl) 2009-08-31
SG131945A1 (en) 2007-05-28
ZA200706854B (en) 2008-09-25
PL1689720T3 (pl) 2009-09-30
IL175539A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
UY28635A1 (es) Derivados de pirazolilo, procedimiento de preparación y productos intermedios de este procedimiento a modo de medicamentos y composiciones farmacéuticas que los contienen.
MX2022014458A (es) Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
UY27713A1 (es) Derivados de aminoindazoles, procedimiento de preparación e intermedios de este procedimiento a título de medicamentos y composiciones farmacéuticas que los contienen,
CR9314A (es) Derivado de espirocetal y uso del mismo como medicina para la diabetes
NO20062135L (no) Fenylderivater som PPAR-agonister
HUP0302487A2 (hu) Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR041009A1 (es) Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
HUP0301117A2 (hu) Imidazolszármazék kináz inhibitorok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW200716527A (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
TW200505453A (en) Non-nucleoside reverse transcriptase inhibitors
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
CL2004000769A1 (es) Compuestos derivados del acido [2-(8,9-dioxo-2,6-diazabiciclo [5,2,o]non-1-(7)-en-2-il) alquil]fosfonico, antagonistas del receptor n-metil-d-aspartato (nmda); procedimiento de preparacion; composicion farmaceutica; y su uso para tratar desordenes va
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
MX2022006003A (es) Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant
CU20210006A7 (es) Derivados de fenil-n-quinolina y proceso para su preparación
ATE384714T1 (de) Pyrazolderivate

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20140326